Abstract
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a recently discovered enzyme that catalyzes the hydrolysis of 3-phosphotyrosyl bonds. Such linkages form in vivo following the DNA processing activity of topoisomerase I (Top1). For this reason, Tdp1 has been implicated in the repair of irreversible Top1-DNA covalent complexes, which can be generated by either exogenous or endogenous factors. Tdp1 has been regarded as a potential therapeutic co-target of Top1 in that it seemingly counteracts the effects of Top1 inhibitors, such as camptothecin and its clinically used derivatives. Thus, by reducing the repair of Top1-DNA lesions, Tdp1 inhibitors have the potential to augment the anticancer activity of Top1 inhibitors provided there is a presence of genetic abnormalities related to DNA checkpoint and repair pathways. Human Tdp1 can also hydrolyze other 3-end DNA alterations including 3-phosphoglycolates and 3-abasic sites indicating it may function as a general 3-DNA phosphodiesterase and repair enzyme. The importance of Tdp1 in humans is highlighted by the observation that a recessive mutation in the human TDP1 gene is responsible for the inherited disorder, spinocerebellar ataxia with axonal neuropathy (SCAN1). This review provides a summary of the biochemical and cellular processes performed by Tdp1 as well as the rationale behind the development of Tdp1 inhibitors for anticancer therapy.
Anti-Cancer Agents in Medicinal Chemistry
Title: Tyrosyl-DNA Phosphodiesterase as a Target for Anticancer Therapy
Volume: 8 Issue: 4
Author(s): Thomas S. Dexheimer, Smitha Antony, Christophe Marchand and Yves Pommier
Affiliation:
Abstract: Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a recently discovered enzyme that catalyzes the hydrolysis of 3-phosphotyrosyl bonds. Such linkages form in vivo following the DNA processing activity of topoisomerase I (Top1). For this reason, Tdp1 has been implicated in the repair of irreversible Top1-DNA covalent complexes, which can be generated by either exogenous or endogenous factors. Tdp1 has been regarded as a potential therapeutic co-target of Top1 in that it seemingly counteracts the effects of Top1 inhibitors, such as camptothecin and its clinically used derivatives. Thus, by reducing the repair of Top1-DNA lesions, Tdp1 inhibitors have the potential to augment the anticancer activity of Top1 inhibitors provided there is a presence of genetic abnormalities related to DNA checkpoint and repair pathways. Human Tdp1 can also hydrolyze other 3-end DNA alterations including 3-phosphoglycolates and 3-abasic sites indicating it may function as a general 3-DNA phosphodiesterase and repair enzyme. The importance of Tdp1 in humans is highlighted by the observation that a recessive mutation in the human TDP1 gene is responsible for the inherited disorder, spinocerebellar ataxia with axonal neuropathy (SCAN1). This review provides a summary of the biochemical and cellular processes performed by Tdp1 as well as the rationale behind the development of Tdp1 inhibitors for anticancer therapy.
Export Options
About this article
Cite this article as:
Dexheimer S. Thomas, Antony Smitha, Marchand Christophe and Pommier Yves, Tyrosyl-DNA Phosphodiesterase as a Target for Anticancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/187152008784220357
DOI https://dx.doi.org/10.2174/187152008784220357 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unknown Primary Squamous Cell Carcinoma of the Head and Neck
Current Cancer Therapy Reviews Genetic Approaches for Antigen-Selective Cell Therapy
Current Gene Therapy Endothelial Cell Aging and Apoptosis in Prevention and Disease: E-Selectin Expression and Modulation As A Model
Current Pharmaceutical Design S-Layer Proteins as Key Components of a Versatile Molecular Construction Kit for Biomedical Nanotechnology
Mini-Reviews in Medicinal Chemistry Current Status and Perspectives in Ceramide-Targeting Molecular Medicine
Current Pharmaceutical Design Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?
Current Clinical Pharmacology Exploring Cancer Therapeutics with Natural Products from African Medicinal Plants, Part II: Alkaloids, Terpenoids and Flavonoids
Anti-Cancer Agents in Medicinal Chemistry Carrier Deformability in Drug Delivery
Current Pharmaceutical Design Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Polymer-based Nanodevices for Effective Antimicrobial Therapy: Synthetic Strategies and Applications
Current Applied Polymer Science Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes
Current Medicinal Chemistry Cystic Fibrosis: New Insights into Therapeutic Approaches
Current Respiratory Medicine Reviews Recent Advances in Apoptosis: THE Role of Hydrazones
Mini-Reviews in Medicinal Chemistry Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Editorial (Thematic Issue: Structure-Function Based Drug Design for Cancer Therapeutics)
Current Pharmaceutical Biotechnology Molecular Sieves in Medicine
Mini-Reviews in Medicinal Chemistry License to Kill Tumors: How Much Hope is Justified for Trail?
Current Pharmaceutical Design GIST and Breast Cancer: 3 Case Reports and a Review of the Literature
Current Cancer Therapy Reviews Fragment Based Drug Design: From Experimental to Computational Approaches
Current Medicinal Chemistry